A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia

Daniel E. Hilleman, Jeffrey O. Phillips, Syed M. Mohiuddin, Kay L. Ryschon, Craig A. Pedersen

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors have become the drugs of choice for the treatment of patients with hypercholesterolemia. However, one of the major concerns with these drugs is cost. In an attempt to develop a cost-effective treatment strategy for patients referred to our lipid clinic, we conducted a meta-analysis to estimate the lipid-lowering efficacy of the various HMG-CoA reductase inhibitors alone or in combination with niacin or cholestyramine. Based on cholesterol-lowering efficacy estimates derived from a literature-based meta- analysis, we performed a population-based treat-to-target analysis. Fifty- six trials with 101 monotherapy cohorts and 20 trials with 31 combination- therapy cohorts (573 patients) were included in the meta-analysis. Based on reduction in low-density lipoprotein cholesterol (LDL-C), the most effective monotherapy was atorvastatin and the least effective monotherapy was fluvastatin. Combination therapy was more effective in reducing LDL-C than monotherapy with the respective HMG-CoA reductase inhibitor. However, on the basis of dollars spent per percentage of LDL-C reduction, combination therapy was frequently less cost-effective than monotherapy. In addition, combination therapy was associated with a higher rate of noncompliance and a greater risk of drug-drug interactions. As a result, we based our treat-to-target analysis on the use of monotherapy as first-line treatment, with combination therapy reserved for patients failing to achieve the target LDL-C levels of the US National Cholesterol Education Program Adult Treatment Panel II (NCEP ATP- II) with monotherapy. In the population-based treat-to-target analysis, atorvastatin was the most cost-effective drug for high-risk patients (those with coronary heart disease [CHD]), whereas fluvastatin was the most cost- effective agent for low-risk patients (

Original languageEnglish
Pages (from-to)536-562
Number of pages27
JournalClinical Therapeutics
Volume21
Issue number3
DOIs
StatePublished - 1999

Fingerprint

Pharmaceutical Economics
Hypercholesterolemia
Oxidoreductases
fluvastatin
LDL Cholesterol
Population
Meta-Analysis
Drug Costs
Therapeutics
Cholesterol
Cholestyramine Resin
Lipids
Costs and Cost Analysis
3-hydroxy-3-methylglutaryl-coenzyme A
Niacin
Drug Interactions
Pharmaceutical Preparations
Health Care Costs
Coronary Disease
Education

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. / Hilleman, Daniel E.; Phillips, Jeffrey O.; Mohiuddin, Syed M.; Ryschon, Kay L.; Pedersen, Craig A.

In: Clinical Therapeutics, Vol. 21, No. 3, 1999, p. 536-562.

Research output: Contribution to journalArticle

@article{ea1ef1738d684a3ba824da212ffe963d,
title = "A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia",
abstract = "The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors have become the drugs of choice for the treatment of patients with hypercholesterolemia. However, one of the major concerns with these drugs is cost. In an attempt to develop a cost-effective treatment strategy for patients referred to our lipid clinic, we conducted a meta-analysis to estimate the lipid-lowering efficacy of the various HMG-CoA reductase inhibitors alone or in combination with niacin or cholestyramine. Based on cholesterol-lowering efficacy estimates derived from a literature-based meta- analysis, we performed a population-based treat-to-target analysis. Fifty- six trials with 101 monotherapy cohorts and 20 trials with 31 combination- therapy cohorts (573 patients) were included in the meta-analysis. Based on reduction in low-density lipoprotein cholesterol (LDL-C), the most effective monotherapy was atorvastatin and the least effective monotherapy was fluvastatin. Combination therapy was more effective in reducing LDL-C than monotherapy with the respective HMG-CoA reductase inhibitor. However, on the basis of dollars spent per percentage of LDL-C reduction, combination therapy was frequently less cost-effective than monotherapy. In addition, combination therapy was associated with a higher rate of noncompliance and a greater risk of drug-drug interactions. As a result, we based our treat-to-target analysis on the use of monotherapy as first-line treatment, with combination therapy reserved for patients failing to achieve the target LDL-C levels of the US National Cholesterol Education Program Adult Treatment Panel II (NCEP ATP- II) with monotherapy. In the population-based treat-to-target analysis, atorvastatin was the most cost-effective drug for high-risk patients (those with coronary heart disease [CHD]), whereas fluvastatin was the most cost- effective agent for low-risk patients (",
author = "Hilleman, {Daniel E.} and Phillips, {Jeffrey O.} and Mohiuddin, {Syed M.} and Ryschon, {Kay L.} and Pedersen, {Craig A.}",
year = "1999",
doi = "10.1016/S0149-2918(00)88308-3",
language = "English",
volume = "21",
pages = "536--562",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "3",

}

TY - JOUR

T1 - A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia

AU - Hilleman, Daniel E.

AU - Phillips, Jeffrey O.

AU - Mohiuddin, Syed M.

AU - Ryschon, Kay L.

AU - Pedersen, Craig A.

PY - 1999

Y1 - 1999

N2 - The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors have become the drugs of choice for the treatment of patients with hypercholesterolemia. However, one of the major concerns with these drugs is cost. In an attempt to develop a cost-effective treatment strategy for patients referred to our lipid clinic, we conducted a meta-analysis to estimate the lipid-lowering efficacy of the various HMG-CoA reductase inhibitors alone or in combination with niacin or cholestyramine. Based on cholesterol-lowering efficacy estimates derived from a literature-based meta- analysis, we performed a population-based treat-to-target analysis. Fifty- six trials with 101 monotherapy cohorts and 20 trials with 31 combination- therapy cohorts (573 patients) were included in the meta-analysis. Based on reduction in low-density lipoprotein cholesterol (LDL-C), the most effective monotherapy was atorvastatin and the least effective monotherapy was fluvastatin. Combination therapy was more effective in reducing LDL-C than monotherapy with the respective HMG-CoA reductase inhibitor. However, on the basis of dollars spent per percentage of LDL-C reduction, combination therapy was frequently less cost-effective than monotherapy. In addition, combination therapy was associated with a higher rate of noncompliance and a greater risk of drug-drug interactions. As a result, we based our treat-to-target analysis on the use of monotherapy as first-line treatment, with combination therapy reserved for patients failing to achieve the target LDL-C levels of the US National Cholesterol Education Program Adult Treatment Panel II (NCEP ATP- II) with monotherapy. In the population-based treat-to-target analysis, atorvastatin was the most cost-effective drug for high-risk patients (those with coronary heart disease [CHD]), whereas fluvastatin was the most cost- effective agent for low-risk patients (

AB - The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors have become the drugs of choice for the treatment of patients with hypercholesterolemia. However, one of the major concerns with these drugs is cost. In an attempt to develop a cost-effective treatment strategy for patients referred to our lipid clinic, we conducted a meta-analysis to estimate the lipid-lowering efficacy of the various HMG-CoA reductase inhibitors alone or in combination with niacin or cholestyramine. Based on cholesterol-lowering efficacy estimates derived from a literature-based meta- analysis, we performed a population-based treat-to-target analysis. Fifty- six trials with 101 monotherapy cohorts and 20 trials with 31 combination- therapy cohorts (573 patients) were included in the meta-analysis. Based on reduction in low-density lipoprotein cholesterol (LDL-C), the most effective monotherapy was atorvastatin and the least effective monotherapy was fluvastatin. Combination therapy was more effective in reducing LDL-C than monotherapy with the respective HMG-CoA reductase inhibitor. However, on the basis of dollars spent per percentage of LDL-C reduction, combination therapy was frequently less cost-effective than monotherapy. In addition, combination therapy was associated with a higher rate of noncompliance and a greater risk of drug-drug interactions. As a result, we based our treat-to-target analysis on the use of monotherapy as first-line treatment, with combination therapy reserved for patients failing to achieve the target LDL-C levels of the US National Cholesterol Education Program Adult Treatment Panel II (NCEP ATP- II) with monotherapy. In the population-based treat-to-target analysis, atorvastatin was the most cost-effective drug for high-risk patients (those with coronary heart disease [CHD]), whereas fluvastatin was the most cost- effective agent for low-risk patients (

UR - http://www.scopus.com/inward/record.url?scp=0032894878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032894878&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(00)88308-3

DO - 10.1016/S0149-2918(00)88308-3

M3 - Article

VL - 21

SP - 536

EP - 562

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 3

ER -